New Tufts CSDD Research Shows Substantial eNPV for DCTs

For the first time ever, Tufts CSDD has completed their initial modeling on the return on investment of decentralized clinical trials.

What did they find?

Phase II studies -  Possible net benefits that are up to 5 times greater than the upfront investment required.

Phase III studies - Possible net benefits that are up to 13 times greater than the upfront investment required.

What other benefits did they find? Complete the form to receive a copy of their research.

Entrust Your Trial to the Number One Provider of DCTs

In August 2021, Everest named Medable the leader in DCT.

Click here to find out why Medable took the number one spot among 15 DCT providers with Everest’s report.

Our First Place Experience

Heading

Heading

Heading

Save the Date!
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
Learn why Tuft's research will transform your trials